论文部分内容阅读
白细胞介素6(IL6)是一种多功能细胞因子,在免疫应答、造血调控和急性期反应中起重要作用。然而,IL6的异常表达与许多自身免疫性疾病和肿瘤的发病机制及发展进程相关。因此,发展针对IL6的拮抗剂将有可能用于这些疾病的治疗。近年来,已有部分IL6拮抗剂用于临床,但多为中和抗体等大分子。由于这些大分子存在相对分子质量大、不易保存、抗原性强等缺点,所以发展新型特异性拮抗IL6的小分子药物将成为治疗IL6表达异常相关疾病的新途径。本文就IL6小分子拮抗剂的研究进行初步探讨。
Interleukin 6 (IL6) is a multifunctional cytokine that plays an important role in immune response, hematopoietic regulation and acute phase response. However, abnormal expression of IL6 is associated with many autoimmune diseases and tumor pathogenesis and progression. Therefore, it would be possible to develop antagonists of IL6 for the treatment of these diseases. In recent years, some IL6 antagonists have been used clinically, but mostly macromolecules such as neutralizing antibodies. Because these macromolecules have the disadvantages of large molecular weight, difficult to preserve and strong antigenicity, the development of new small-molecule drugs that specifically antagonize IL6 will become a new way to treat the diseases related to the abnormal expression of IL6. This article on the IL6 small molecule antagonist research.